Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicaid | 19 | 2026 | 375 | 4.370 |
Why?
|
| Nursing Homes | 15 | 2026 | 686 | 4.140 |
Why?
|
| Atrial Fibrillation | 8 | 2025 | 884 | 2.760 |
Why?
|
| Anticoagulants | 10 | 2025 | 529 | 2.760 |
Why?
|
| Accountable Care Organizations | 10 | 2026 | 74 | 2.710 |
Why?
|
| Dementia | 5 | 2026 | 280 | 2.380 |
Why?
|
| Homes for the Aged | 4 | 2026 | 166 | 2.110 |
Why?
|
| Medicare | 12 | 2026 | 627 | 1.860 |
Why?
|
| United States | 39 | 2026 | 8148 | 1.760 |
Why?
|
| Stroke | 5 | 2023 | 1213 | 1.420 |
Why?
|
| Health Care Costs | 5 | 2026 | 224 | 1.410 |
Why?
|
| Ambulatory Care | 2 | 2025 | 317 | 1.260 |
Why?
|
| Cross-Sectional Studies | 18 | 2026 | 2721 | 1.220 |
Why?
|
| Hospitalization | 9 | 2026 | 1399 | 1.200 |
Why?
|
| Hospice Care | 3 | 2025 | 75 | 1.150 |
Why?
|
| Aged | 28 | 2026 | 15052 | 1.120 |
Why?
|
| Food Assistance | 2 | 2025 | 24 | 1.080 |
Why?
|
| Hospices | 3 | 2025 | 39 | 1.050 |
Why?
|
| Aged, 80 and over | 19 | 2026 | 5644 | 1.030 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 766 | 1.000 |
Why?
|
| Memantine | 2 | 2024 | 22 | 1.000 |
Why?
|
| Humans | 59 | 2026 | 65463 | 0.940 |
Why?
|
| Warfarin | 3 | 2025 | 125 | 0.900 |
Why?
|
| Massachusetts | 12 | 2026 | 2153 | 0.900 |
Why?
|
| Nootropic Agents | 1 | 2025 | 14 | 0.890 |
Why?
|
| Atrial Flutter | 1 | 2025 | 33 | 0.890 |
Why?
|
| Nutritional Support | 1 | 2025 | 12 | 0.890 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 265 | 0.880 |
Why?
|
| Emergency Service, Hospital | 6 | 2026 | 1161 | 0.850 |
Why?
|
| Psychotropic Drugs | 1 | 2025 | 81 | 0.850 |
Why?
|
| Antidepressive Agents | 1 | 2026 | 233 | 0.840 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 80 | 0.820 |
Why?
|
| Male | 33 | 2026 | 31187 | 0.800 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2021 | 15 | 0.800 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 41 | 0.780 |
Why?
|
| Female | 33 | 2026 | 34193 | 0.770 |
Why?
|
| Inappropriate Prescribing | 2 | 2021 | 68 | 0.760 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 38 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 708 | 0.680 |
Why?
|
| Medicare Part C | 1 | 2021 | 14 | 0.660 |
Why?
|
| Administration, Oral | 4 | 2024 | 371 | 0.660 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 409 | 0.650 |
Why?
|
| Mental Disorders | 2 | 2026 | 822 | 0.640 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 142 | 0.630 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2026 | 504 | 0.620 |
Why?
|
| Depression | 1 | 2026 | 903 | 0.590 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 303 | 0.580 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.570 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.570 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 294 | 0.570 |
Why?
|
| Health Equity | 3 | 2025 | 55 | 0.560 |
Why?
|
| Italy | 6 | 2021 | 69 | 0.550 |
Why?
|
| Brain Ischemia | 2 | 2019 | 418 | 0.550 |
Why?
|
| Metformin | 1 | 2019 | 77 | 0.540 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.530 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 11 | 0.530 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 166 | 0.520 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 51 | 0.500 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 225 | 0.490 |
Why?
|
| Deprescriptions | 3 | 2026 | 29 | 0.480 |
Why?
|
| Middle Aged | 16 | 2026 | 18387 | 0.470 |
Why?
|
| Meals | 2 | 2026 | 27 | 0.470 |
Why?
|
| Cohort Studies | 5 | 2024 | 2633 | 0.460 |
Why?
|
| General Practitioners | 1 | 2015 | 14 | 0.450 |
Why?
|
| Hemorrhage | 3 | 2024 | 286 | 0.440 |
Why?
|
| Drug Utilization | 3 | 2021 | 204 | 0.430 |
Why?
|
| Adult | 13 | 2026 | 17461 | 0.420 |
Why?
|
| Nurses | 1 | 2015 | 114 | 0.400 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 50 | 0.400 |
Why?
|
| Cost of Illness | 1 | 2014 | 169 | 0.390 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6929 | 0.390 |
Why?
|
| Biopsy | 1 | 2014 | 460 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 744 | 0.370 |
Why?
|
| Managed Care Programs | 2 | 2025 | 86 | 0.370 |
Why?
|
| Patient Care Team | 1 | 2015 | 336 | 0.370 |
Why?
|
| Mammography | 1 | 2014 | 292 | 0.350 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 165 | 0.350 |
Why?
|
| Health Care Surveys | 2 | 2025 | 288 | 0.350 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5806 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 326 | 0.330 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 71 | 0.330 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 628 | 0.320 |
Why?
|
| Primary Health Care | 3 | 2025 | 723 | 0.320 |
Why?
|
| Quality of Life | 1 | 2017 | 1263 | 0.310 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 249 | 0.310 |
Why?
|
| Mass Screening | 1 | 2014 | 700 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 599 | 0.280 |
Why?
|
| Drug Monitoring | 2 | 2022 | 203 | 0.280 |
Why?
|
| Qualitative Research | 4 | 2026 | 757 | 0.280 |
Why?
|
| Patient Readmission | 2 | 2026 | 452 | 0.270 |
Why?
|
| Cognition Disorders | 2 | 2021 | 224 | 0.270 |
Why?
|
| Sex Factors | 3 | 2021 | 995 | 0.260 |
Why?
|
| Medicare Part D | 2 | 2025 | 36 | 0.260 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 804 | 0.250 |
Why?
|
| Age Factors | 3 | 2021 | 1592 | 0.240 |
Why?
|
| Child | 4 | 2025 | 4623 | 0.240 |
Why?
|
| Polypharmacy | 1 | 2026 | 67 | 0.230 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 8 | 0.230 |
Why?
|
| Cost Savings | 1 | 2026 | 60 | 0.230 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 68 | 0.230 |
Why?
|
| Time Factors | 3 | 2019 | 3774 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1231 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2026 | 370 | 0.220 |
Why?
|
| Health Care Reform | 2 | 2023 | 86 | 0.220 |
Why?
|
| Social Determinants of Health | 3 | 2022 | 150 | 0.220 |
Why?
|
| Diet Therapy | 1 | 2025 | 15 | 0.220 |
Why?
|
| Residence Characteristics | 3 | 2023 | 230 | 0.220 |
Why?
|
| Nurse Administrators | 1 | 2024 | 19 | 0.210 |
Why?
|
| Research Design | 2 | 2025 | 590 | 0.210 |
Why?
|
| Prescription Drugs | 1 | 2025 | 49 | 0.210 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 46 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 181 | 0.210 |
Why?
|
| Naphthalenesulfonates | 1 | 2023 | 3 | 0.200 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2776 | 0.200 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.190 |
Why?
|
| Comorbidity | 3 | 2021 | 1120 | 0.190 |
Why?
|
| Social Responsibility | 1 | 2022 | 12 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 95 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 704 | 0.190 |
Why?
|
| Motivation | 2 | 2026 | 298 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1284 | 0.190 |
Why?
|
| Pediatrics | 1 | 2024 | 264 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2025 | 742 | 0.180 |
Why?
|
| Racism | 1 | 2023 | 93 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 769 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 63 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2021 | 33 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 139 | 0.170 |
Why?
|
| Drug Repositioning | 1 | 2021 | 11 | 0.170 |
Why?
|
| Risk Factors | 2 | 2023 | 5458 | 0.170 |
Why?
|
| Young Adult | 5 | 2025 | 4837 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 348 | 0.150 |
Why?
|
| Cognition | 1 | 2023 | 510 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2020 | 104 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.140 |
Why?
|
| Epilepsy | 1 | 2020 | 113 | 0.140 |
Why?
|
| Interviews as Topic | 3 | 2026 | 532 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 354 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 69 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.140 |
Why?
|
| Adolescent | 4 | 2025 | 6332 | 0.130 |
Why?
|
| Health Services Research | 1 | 2019 | 265 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 165 | 0.130 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 22 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 96 | 0.130 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 39 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 899 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 482 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 58 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 120 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 152 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2017 | 216 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 59 | 0.110 |
Why?
|
| Physician-Nurse Relations | 1 | 2015 | 26 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2015 | 75 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2017 | 275 | 0.110 |
Why?
|
| Medicine | 1 | 2015 | 53 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 295 | 0.110 |
Why?
|
| False Positive Reactions | 1 | 2014 | 77 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 137 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 254 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 828 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 98 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 529 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 523 | 0.100 |
Why?
|
| Poverty | 2 | 2026 | 307 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 921 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 498 | 0.080 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 76 | 0.080 |
Why?
|
| Pharmacists | 2 | 2023 | 131 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2023 | 533 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 1451 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 113 | 0.060 |
Why?
|
| Consensus | 1 | 2025 | 177 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 235 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2024 | 202 | 0.050 |
Why?
|
| Health Policy | 1 | 2025 | 191 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 74 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 220 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 94 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 82 | 0.050 |
Why?
|
| Income | 1 | 2023 | 169 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 36 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2021 | 30 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 202 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2021 | 53 | 0.040 |
Why?
|
| Palliative Care | 1 | 2023 | 250 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 847 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 230 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 293 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 468 | 0.040 |
Why?
|
| Senior Centers | 1 | 2017 | 1 | 0.030 |
Why?
|
| Communication | 1 | 2023 | 600 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 385 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 84 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 106 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 14 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 394 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 296 | 0.030 |
Why?
|
| Health Resources | 1 | 2017 | 92 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 929 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 117 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 419 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 192 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 682 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 162 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 857 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 931 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1430 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 384 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 104 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 322 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 887 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 755 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 1223 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2492 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2111 | 0.020 |
Why?
|